Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $365 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a $365 price target.
May 30, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Vertex Pharmaceuticals and maintained a $365 price target.
The Overweight rating from Cantor Fitzgerald analyst Olivia Brayer indicates a positive outlook for Vertex Pharmaceuticals. The maintained $365 price target suggests that the stock has potential for growth in the short term. This news is directly related to VRTX and is important for investors as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100